Mark Hensley
Fortune : 84 767 $ au 31/07/2026
Fortune : 84 767 $ au 31/07/2026
Mark E.
Hensley is currently Chairman at Calliditas Therapeutics AB and Chief Operating Officer & Executive Vice President at Heron Therapeutics, Inc. starting in 2025.
Formerly, Mr. Hensley was Chief Commercial Officer at Veloxis Pharmaceuticals A from 2018 to 2021.
Education includes an undergraduate degree from the University of North Texas.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HERON THERAPEUTICS INC 0,09 % | 06/08/2026 | 170 901 ( 0,09 % ) | 84 767 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Président | - |
| HERON THERAPEUTICS, INC. | Directeur des opérations | 28/04/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Corporate Officer/Principal | 01/01/2021 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Heron Therapeutics, Inc.
Heron Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and commercializes of polymer technologies | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
University of North Texas
University of North Texas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Calliditas Therapeutics AB
Calliditas Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national